Next, we developed an in vitro antibody binding/uptake assay to enable selection of an antibody with optimized affinity such that binding and uptake by EGFR occurs more efficiently on overexpressing cancer cells compared to normal cells. The gene discussed is EGFR; the disease is cancer.